Pete Olson, PhD, is the Chief Scientific Officer at Iambic Therapeutics, a clinical-stage biotechnology company accelerating drug discovery by leveraging AI models for protein structure prediction and wholistic drug design with high-throughput chemistry and biology experimentation. Prior to Iambic, he was most recently VP, Research at Mirati Therapeutics, which was acquired by Bristol Myers Squibb in Jan, 2024. Here he built a successful track record running in vitro and in vivo biology / pharmacology functions to drive small molecule oncology programs from target identification to clinical proof-of-concept. He has deep experience targeting oncogenic driver and synthetic lethal cancer pathways and developing robust pre-clinical data packages that generate clinically-testable precision medicine hypotheses. During his tenure, several programs reached the clinic including adagrasib (KRAS G12C inhibitor; FDA approved; KRAZATI), BMS-986504 (previously MRTX1719; MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers), MRTX1133 (KRAS G12D inhibitor), MRTX0902 (SOS1 inhibitor) and ORIC-944 (EED (PRC2) inhibitor out licensed to ORIC Pharmaceuticals). Prior to Mirati, Pete was a Senior Group Leader in the Pfizer Oncology Research Unit where he led projects including translational research for the Gamma Secretase Inhibitor (GSI) program out licensed to SpringWorks Therapeutics (nirogacestat; OGSIVEO; FDA approved). He has over 25 years of basic, pre-clinical and translational research experience across academia and industry.